Home » Stocks » TOCA

Tocagen Inc. (TOCA)

Jun 16, 2020 - TOCA merged into FBRX
Stock Price: $1.26 USD 0.00 (0.00%)
Updated Jun 15, 2020 4:00 PM EDT
Market Cap 2.01M
Revenue (ttm) 27,000
Net Income (ttm) n/a
Shares Out 23.92M
EPS (ttm) -2.38
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day Jun 15, 2020
Last Price $1.26
Previous Close $1.26
Change ($) 0.00
Change (%) 0.00%
Day's Open -
Day's Range 1.22 - 1.50
Day's Volume 0
52-Week Range 0.42 - 6.77

News

Hide News
PRNewsWire - 9 months ago

SAN DIEGO, May 28, 2020 /PRNewswire/ -- Tocagen Inc. (Nasdaq: TOCA), historically a clinical-stage, cancer-selective gene therapy company, announced today that, due to public health and safety...

Seeking Alpha - 1 year ago

Tocagen Inc. (TOCA) Tocagen and Forte Biosciences Announce Merger (Transcript)

Benzinga - 1 year ago

Tocagen Inc (NASDAQ: TOCA) shares were tumbling to an all-time low Thursday following an adverse clinical trial readout.

Market Watch - 1 year ago

Shares of Tocagen Inc. TOCA, +11.47% plummeted 82% on heavy volume toward a record low, enough to pace all premarket decliners Thursday, after the gene company said a late-stage trial of its b...

Zacks Investment Research - 1 year ago

Investors need to pay close attention to Tocagen (TOCA) stock based on the movements in the options market lately.

Zacks Investment Research - 1 year ago

TOCAGEN INC (TOCA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Seeking Alpha - 1 year ago

The final data read-out of Toca 5 Pivotal phase III trial in patient with Recurrent Brain Cancer anticipated in Q4 2019.

Seeking Alpha - 1 year ago

Investors overreacted to Tocagen’s recent announcement that an Independent Data Monitoring Committee (IDMC) gave its brain cancer drug clinical trials the go-ahead to continue.

Zacks Investment Research - 1 year ago

Investors need to pay close attention to Tocagen (TOCA) stock based on the movements in the options market lately.

The Motley Fool - 1 year ago

An interim look at the company's experimental brain cancer treatment didn't reveal the result investors wanted.

Zacks Investment Research - 1 year ago

Investors need to pay close attention to Tocagen (TOCA) stock based on the movements in the options market lately.

Seeking Alpha - 1 year ago

Today, we take a "deep-dive" on an interesting developmental name in oncology named Tocagen based in sunny San Diego.

About TOCA

Tocagen, a clinical-stage cancer-selective gene therapy company, focuses on developing and commercializing product candidates designed to activate a patient's immune system against their cancer. Its cancer-selective gene therapy platform is built on retroviral replicating vectors (RRVs), which are designed to deliver therapeutic genes into the DNA of cancer cells. The company's lead product candidate is Toca 511 & Toca FC that is under Phase III clinical trial for recurrent high-grade glioma. It is also developing Toca 511 & Toca FC in a Phase ... [Read more...]

Industry
Biotechnology
IPO Date
Apr 13, 2017
CEO
Martin J. Duvall
Employees
9
Stock Exchange
NASDAQ
Ticker Symbol
TOCA
Full Company Profile

Financial Performance

In 2019, Tocagen's revenue was $36,000, a decrease of -99.80% compared to the previous year's $18.04 million. Losses were -$63.52 million, 29.7% more than in 2018.

Financial Statements